SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-083753
Filing Date
2020-07-15
Accepted
2020-07-15 16:37:39
Documents
13
Period of Report
2020-07-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2019110-5_8k.htm   iXBRL 8-K 34541
2 EXHIBIT 99.1 tm2019110d5_ex99-1.htm EX-99.1 18692
  Complete submission text file 0001104659-20-083753.txt   239492

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20200715.xsd EX-101.SCH 3183
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20200715_lab.xml EX-101.LAB 34591
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20200715_pre.xml EX-101.PRE 22708
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2019110-5_8k_htm.xml XML 3745
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 201029451
SIC: 2834 Pharmaceutical Preparations